Scholarlink

<p>The clinical efficacy of potent multimodal cancer therapies is often compromised by severe systemic toxicities, particularly cardiotoxicity. To address this critical challenge, we report a hierarchically engineered metal-organic framework (MOF) nanoplatform that integrates a therapeutic arsenal with a preemptive organ-protective strategy. This is achieved by encapsulating the chemotherapeutic agent curcumin (CCM) within a pH-labile ZIF-8 core, which is then surface-decorated with gold nanoparticles (AuNPs) that serve as both photothermal agents and anchors for the cardioprotective natural product, naringin (NA). This unique architecture facilitates a programmed, biphasic release profile: the surface-bound NA is rapidly released first to exert systemic cardioprotective effects, followed by the targeted, acid-triggered release of CCM at the tumor site. The integrated Au nanoparticles enable mild photothermal therapy (&lt;45 °C) that synergizes with chemotherapy. Both in vitro and <i>in vivo</i> experiments confirmed the platform’s outstanding therapeutic performance, achieving a tumor inhibition rate as high as 97.5% while simultaneously maintaining normal levels of the cardiac damage marker creatine kinase (CK). This study pioneers a “therapy-protection integration” strategy, offering a new paradigm for designing advanced nanomedicines that are not only highly effective but also fundamentally safer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A MOF-based nanoplatform integrating cardioprotection with chemo-photothermal therapy for safer cancer treatment

  • 期刊论文

  • 发表日期：

    2026年2月3日

查看全文
  • Zitian Zhuang,
  • Yehong Wan,
  • Xueping Yan,
  • Ling Zhang,
  • Ke Jiang

摘要

The clinical efficacy of potent multimodal cancer therapies is often compromised by severe systemic toxicities, particularly cardiotoxicity. To address this critical challenge, we report a hierarchically engineered metal-organic framework (MOF) nanoplatform that integrates a therapeutic arsenal with a preemptive organ-protective strategy. This is achieved by encapsulating the chemotherapeutic agent curcumin (CCM) within a pH-labile ZIF-8 core, which is then surface-decorated with gold nanoparticles (AuNPs) that serve as both photothermal agents and anchors for the cardioprotective natural product, naringin (NA). This unique architecture facilitates a programmed, biphasic release profile: the surface-bound NA is rapidly released first to exert systemic cardioprotective effects, followed by the targeted, acid-triggered release of CCM at the tumor site. The integrated Au nanoparticles enable mild photothermal therapy (<45 °C) that synergizes with chemotherapy. Both in vitro and in vivo experiments confirmed the platform’s outstanding therapeutic performance, achieving a tumor inhibition rate as high as 97.5% while simultaneously maintaining normal levels of the cardiac damage marker creatine kinase (CK). This study pioneers a “therapy-protection integration” strategy, offering a new paradigm for designing advanced nanomedicines that are not only highly effective but also fundamentally safer.